Gossamer Bio, Inc. (GOSS)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 11.5M | 13.3M | 13.8M | 17.0M |
| Operating Income | -38.8M | -41.6M | -46.0M | -44.9M |
| Net Income | -38.3M | -48.2M | -47.2M | -46.7M |
| Diluted EPS | $-0.17 | $-0.21 | $-0.21 | $-0.20 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 114.7M | 48.5M |
| Operating Income | -218.5M | -173.8M | -59.9M | -163.3M |
| Net Income | -229.4M | -179.8M | -56.5M | -170.4M |
| Diluted EPS | $-2.71 | $-1.18 | $-0.25 | $-0.75 |